| __timestamp | BioMarin Pharmaceutical Inc. | Incyte Corporation |
|---|---|---|
| Wednesday, January 1, 2014 | 129764000 | 3004000 |
| Thursday, January 1, 2015 | 152008000 | 26972000 |
| Friday, January 1, 2016 | 209620000 | 58187000 |
| Sunday, January 1, 2017 | 241786000 | 79479000 |
| Monday, January 1, 2018 | 315264000 | 94123000 |
| Tuesday, January 1, 2019 | 359466000 | 114249000 |
| Wednesday, January 1, 2020 | 524272000 | 131328000 |
| Friday, January 1, 2021 | 470515000 | 150991000 |
| Saturday, January 1, 2022 | 483669000 | 206997000 |
| Sunday, January 1, 2023 | 577065000 | 255000000 |
| Monday, January 1, 2024 | 580235000 | 312068000 |
Unlocking the unknown
In the ever-evolving pharmaceutical landscape, understanding cost structures is pivotal. From 2014 to 2023, BioMarin Pharmaceutical Inc. and Incyte Corporation have showcased distinct financial trajectories. BioMarin's cost of revenue surged by approximately 345%, peaking in 2023, reflecting its aggressive expansion and innovation strategies. In contrast, Incyte Corporation, while experiencing a significant 8,400% increase, maintained a more conservative cost profile, indicative of its strategic focus on niche markets.
These insights underscore the diverse strategies within the pharmaceutical sector, offering a window into how companies balance growth with cost management.
Analyzing Cost of Revenue: Sanofi and BioMarin Pharmaceutical Inc.
Cost of Revenue Trends: Vertex Pharmaceuticals Incorporated vs Incyte Corporation
Cost of Revenue: Key Insights for Neurocrine Biosciences, Inc. and Incyte Corporation
Research and Development Expenses Breakdown: Incyte Corporation vs BioMarin Pharmaceutical Inc.
Cost Insights: Breaking Down Incyte Corporation and ACADIA Pharmaceuticals Inc.'s Expenses
Comparing Cost of Revenue Efficiency: Incyte Corporation vs Dyne Therapeutics, Inc.
Incyte Corporation vs Viridian Therapeutics, Inc.: Efficiency in Cost of Revenue Explored
Cost of Revenue: Key Insights for Dr. Reddy's Laboratories Limited and BioMarin Pharmaceutical Inc.
BioMarin Pharmaceutical Inc. vs Exelixis, Inc.: Efficiency in Cost of Revenue Explored
Analyzing Cost of Revenue: BioMarin Pharmaceutical Inc. and Telix Pharmaceuticals Limited
Cost Insights: Breaking Down BioMarin Pharmaceutical Inc. and Xenon Pharmaceuticals Inc.'s Expenses
BioMarin Pharmaceutical Inc. vs ACADIA Pharmaceuticals Inc.: Efficiency in Cost of Revenue Explored